Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
Want to see HK:2185 full AI Analyst Report?
2185 Stock Chart & Stats
HK$5.71
HK$0.03(1.94%)
At close: 4:00 PM EST
HK$5.71
HK$0.03(1.94%)
Day’s Range― - ―
52-Week RangeHK$2.79 - HK$10.77
Previous CloseN/A
Volume27.00K
Average Volume (3M)2.14M
Market Cap
HK$684.00M
Enterprise ValueHK$535.26M
Total Cash (Recent Filing)HK$248.63M
Total Debt (Recent Filing)HK$12.73M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low debt provides durable financial flexibility for a development-stage biotech. Minimal leverage reduces refinancing and interest burden risks, allowing the company to prioritize R&D and clinical timelines, extend runway via equity or partnerships, and better absorb operating volatility over the medium term.
Revenue Rebound In 2025A material revenue rebound indicates early commercial traction or recovery in operations, which is a durable signal if sustained. Growing top-line can enable scale economies, help absorb fixed R&D costs, and provide the foundation for margin improvement and reduced external funding reliance over the next several quarters.
Focused R&D / Lean OrganizationA small, specialized headcount and explicit focus on regenerative medicine suggest concentrated technical capability and lower fixed overhead. Lean operations can extend cash runway, deliver faster decision cycles in clinical programs, and improve capital efficiency—advantages that endure through development milestones.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the company depends on external financing to sustain operations. Over months this raises dilution and execution risk, constrains strategic optionality, and can force trade-offs between R&D priorities or delay programs if additional funding terms become unfavorable.
Unprofitable Operations / Negative MarginsNegative gross profit and large operating losses reflect fundamental issues with unit economics or scale. Without structural improvement in margins or sustained revenue growth, losses will persist, eroding returns and making it difficult to achieve self-sustaining operations over the medium term.
Eroding Equity BaseDeclining equity and negative ROE show cumulative losses are shrinking the capital base. Over several quarters this reduces the cushion for further losses, limits borrowing capacity without onerous terms, and increases the likelihood of dilutive funding or strategic concessions to secure necessary capital.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$2.79 and its highest was HK$10.77 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$684.00M.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Jul 31, 2026 which is in 53 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.193 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.193.
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 235,703,410 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.193 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.308%.
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.50%
12-Months-Change
Fundamentals
Return on Equity
-15.19%
Trailing 12-Months
Asset Growth
18.74%
Trailing 12-Months
Company Description
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) Earnings & Revenues
Technical Analysis
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Wuhan YZY Biopharma Co., Ltd. Class H
―
Sunho Biologics,Inc.
―
Options Prices
Currently, No data available
---